Complete Bibliography
Visit PubMed to view Dr. Chapuis' complete publication record.
Selected Publications
Mazziotta F, Martin LE, Egan DN, Bar M, Kinsella S, Paulson KG, Voillet V, Lahman MC, Hunter D, Schmitt TM, Duerkopp N, Yeung CCS, Tang TH, Gottardo R, Asano Y, Wilcox EC, Lee B, Zhang T, Lopedote P, Penter L, Wu CJ, Milano F, Greenberg PD, Chapuis AG. A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0. PubMed PMID: 40473616; PubMed Central PMCID: PMC12141728.
Zhang S, Tang TH, Kinsella S, Mazziotta F, Schweizer MT, McAfee MS, Munkhbat A, Su Y, Voillet V, Martin LE, Smith CW, Asano Y, Hailemariam M, Bakhtiari J, Lee B, Yeung C, Chen H, Rizzi AM, Chen DG, Furiya K, Horst N, Zhang T, Le P, McKenna K, Oda SK, Rongvaux A, Greenberg PD, Schmitt TM, Chapuis AG. A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands. Nat Commun. 2026 Jan 3;17(1):753. doi: 10.1038/s41467-025-67446-5. PMID: 41484084 Free PMC article.
Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, Koelle DM, Pierce RH, Bielas JH, Greenberg PD, Bhatia S, Gottardo R, Nghiem P, Chapuis AG. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018 Sep 24;9(1):3868.
Chapuis AG, Egan DN, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gorttardo R, Ragnarsson GB, Bleakley M, Yeung CC, Mulhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath J, Duerkopp N, Gooley TA, Greenberg PD. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019 Published online 24 June.
Ecsedi M, McAfee MS, Chapuis AG. The Anticancer Potential of T Cell Receptor-Engineered T Cells. Trends Cancer. 2021 Jan;7(1):48-56. Epub 2020 Sep 26.
Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, Voillet V, Martin L, Gottardo R, Bielas J, McElrath JM, Stirewalt DL, Pogosova-Agadjanyan EL, Yeung CC, Pierce RH, Egan DN, Bar M, Hendrie PC, Kinsella S, Vakil A, Butler J, Chaffee M, Linton J, McAfee MS, Hunter DS, Bleakley M, Rongvaux A, Van den Eynde BJ, Chapuis AG, Greenberg PD. Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci Transl Med. 2022 Feb 9;14(631):eabg8070. Epub 2022 Feb 9.
Schmitt TM, Furiya K, Black C, Vazquez A, Sharma J, Hailemariam M, Paushter DH, Trieu L, Lam J, Lee B, Rakhra K, Whalen KA, Mehta NK, Sauer K, Baeuerle PA, Michaelson JS, Greenberg PD, Chapuis AG. Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics. J Immunother Cancer. 2026 Feb 4;14(2):e013520. doi: 10.1136/jitc-2025-013520. PMID: 41638872; PMCID: PMC12878313.